Biofrontera Inc. (BFRIW) income statement

BFRIWNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BFRI

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 10/30

$0.00+0.00 (0.00%)

Close on Oct 30, 2026Market cap $12.96MP/E –Yield –

Biofrontera Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31	Q3 2024 2024-09-30	Q2 2024 2024-06-30	Q1 2024 2024-03-31	Q4 2023 2023-12-31	Q3 2023 2023-09-30	Q2 2023 2023-06-30	Q1 2023 2023-03-31	Q4 2022 2022-12-31	Q3 2022 2022-09-30	Q2 2022 2022-06-30	Q1 2022 2022-03-31	Q4 2021 2021-12-31	Q3 2021 2021-09-30	Q2 2021 2021-06-30	Q1 2021 2021-03-31	Q4 2020 2020-12-31	Q3 2020 2020-09-30
Revenue	12	10	17	6.99	9.03	8.59	13	9.01	7.84	7.91	11	8.90	5.85	8.73	10	4.32	4.46	9.75	9.17	4.33	5.86	4.74	8.57	3.25
Cost of Revenue	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.04	–	–	–	0.45
Gross Profit	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	4.29	–	–	–	2.81
Research & Development	0.45	0.90	0.79	0.85	0.87	1.21	0.78	0.67	0.62	0.02	0.03	0.03	0.01	–	–	–	–	–	–	–	–	–	–	–
Selling, General & Admin	9.63	11	8.52	10	11	8.65	8.20	8.43	7.92	9.25	9.10	8.62	11	9.80	10	7.77	9.67	7.62	9.10	17	5.55	4.76	4.15	4.19
General & Administrative	4.40	5.73	6.30	5.55	6.46	4.55	4.98	3.85	3.29	4.16	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Operating Expenses	13	14	–	–	14	13	14	14	13	13	14	14	15	14	16	7.96	11	13	11	20	9.54	8.27	–	–
Total Costs & Expenses	13	14	13	13	14	13	14	14	13	13	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Operating Income	-0.52	-4.32	4.56	-6.28	-5.08	-4.55	-1.71	-4.96	-5.07	-5.47	-3.87	-4.62	-8.70	-5.49	-5.62	-3.64	-6.21	-3.11	-1.88	-16	-3.69	-3.53	-0.19	-2.34
Interest Expense	–	–	–	–	–	0.12	–	–	0.62	1.42	-0.04	0.14	0.03	0.00	-0.15	0.09	0.04	0.00	0.09	0.09	0.09	0.08	0.76	0.74
Interest & Investment Income	–	–	–	–	–	0.01	0.02	0.02	–	0.01	0.02	0.01	0.00	0.06	0.00	0.00	0.00	0.06	0.00	0.00	0.00	–	0.01	0.01
Income from Equity Investments	–	–	0.00	0.00	–	–	0.00	0.00	-0.01	0.00	-0.79	-2.21	-1.48	-2.94	–	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	-0.06	-0.43	1.08	-0.37	-0.22	0.34	0.31	-0.71	4.83	-4.97	7.39	-1.72	-1.12	-1.98	2.84	1.07	5.36	8.70	-13	0.10	0.07	-0.01	0	-0.58
Merger & Restructuring Charges	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	0	0	0	0.10	0.20	0.19	0.28	0.27	0.18
Gain (Loss) on Investments	0.00	–	0.00	0.00	0.00	–	0.00	0.00	-0.01	0.00	-0.79	-2.21	-1.48	-2.94	–	–	–	–	–	–	–	–	–	–
Pretax Income	-0.58	-4.75	5.64	-6.64	-5.30	-4.20	-1.40	-5.67	-0.24	-10	3.52	-6.34	-9.82	-7.47	-2.78	-2.57	-0.85	5.59	-15	-16	-3.62	-3.53	-0.19	-2.92
Income Tax Expense	0.02	–	0	0.01	0.02	0.00	0.00	0.00	0.02	0.00	-0.01	0.00	0.01	0.01	0.00	0.00	0	0.03	0.01	0.01	0.04	0.00	0.00	0.06
Net Income	-0.60	-4.75	5.64	-6.65	-5.32	-4.20	-1.40	-5.67	-0.26	-10	3.53	-6.34	-9.84	-7.48	-2.79	-2.57	-0.85	5.56	-15	-16	-3.66	-3.53	-0.19	-2.99
Net Income to Common	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-15	-16	–	–	-0.19	-2.99
EPS (Basic)(per share)	-0.05	-0.41	0.48	-0.62	-0.57	-0.47	–	-0.98	-0.05	-2.88	–	-4.64	-7.23	-5.60	–	-2.26	-0.90	6.60	-25.83	-40.00	-9.20	-8.80	–	-59,693.40
EPS (Diluted)(per share)	-0.05	-0.41	0.48	-0.62	-0.57	-0.47	–	-0.98	-0.05	-2.88	–	-4.64	-7.23	-5.60	–	-2.26	-0.90	6.40	-25.83	-40.00	-9.20	-8.80	–	-59,693.40
Shares Outstanding (Basic, Weighted)(shares)	13	12	12	11	9.35	8.87	7.57	5.77	5.09	3.62	2.15	1.37	1.36	1.33	1.29	1.14	0.94	0.86	0.56	0.40	0.40	0.40	–	0.00
Shares Outstanding (Diluted, Weighted)(shares)	13	12	12	11	9.35	8.87	7.57	5.77	5.09	3.62	2.15	1.37	1.36	1.33	1.29	1.14	0.94	0.86	0.56	0.40	0.40	0.40	–	0.00
EBITDA	-0.46	-4.27	–	–	-5.05	-4.52	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Interest Income	–	–	–	–	–	–	–	–	-0.60	-1.41	-0.21	-0.14	-0.08	-0.04	-0.04	-0.09	-0.04	-0.03	-0.09	-0.09	-0.09	-0.08	-0.76	-0.74

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -14.2%
Net margin: -13.8%
Return on equity, FY2025: -141.3%

Financial strength

Current ratio: 1.18
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 44.2%

Valuation

P/E ratio: –
Price to sales: 0.28
Price to book: 2.18
Dividend yield: –